FIELD: chemical industry.
SUBSTANCE: compound III and its crystalline form A, characterized by an X-ray powder diffractogram (XPDR) containing characteristic diffraction peaks at angle values of 2θ: 4,72 ± 0,2°, 14,24 ± 0,2°, 16,28 ± 0,2°, 17,14 ± 0,2°, 20,72 ± 0,2°, 21,78 ± 0,2°, 23,98 ± 0,2° и 24,96 ± 0,2°. Compound III of the invention or its crystalline form A is used for the preparation of a drug for the treatment of a disease associated with LSD1. Also, compound III of the invention or its crystalline form A are used for the preparation of a drug for the treatment of lung cancer.
EFFECT: compound III and its crystalline form as LSD1 inhibitor.
12 cl, 6 tbl, 4 dwg, 7 ex
Compound III
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUND OF BRD4 INHIBITOR IN SOLID FORM, METHOD FOR ITS PRODUCTION AND APPLICATION | 2020 |
|
RU2793346C1 |
| SALTS AND CRYSTALLINE FORMS OF DIAZABENZOFLUORANTHENE COMPOUNDS | 2017 |
|
RU2762189C2 |
| CRYSTAL FORM OF COMPOUND OF 1H-IMIDAZO[4,5-b]PYRIDINE-2(3H)-ONE AND ITS PRODUCTION METHOD | 2019 |
|
RU2784538C2 |
| SALT FORM OF ISOQUINOLINONE TYPE COMPOUND AS ROCK INHIBITOR AND METHOD FOR ITS PREPARATION | 2021 |
|
RU2821792C1 |
| CRYSTALLINE AND SALT FORMS OF THE TGF-βR1 INHIBITOR AND THE METHOD OF OBTAINING THEM | 2018 |
|
RU2750702C1 |
| ACID ADDITION SALT OF TRK INHIBITING COMPOUND | 2015 |
|
RU2708236C2 |
| INDAZOLE DERIVATIVE SALTS AND THEIR CRYSTALS | 2017 |
|
RU2747399C2 |
| CRYSTALLINE FORM OF SMAC MIMETIC USED AS IAP INHIBITOR, AND METHOD FOR PRODUCTION THEREOF | 2020 |
|
RU2819398C2 |
| CRYSTAL (6S,9AS)-N-BENZYL-8-({6-[3-(4-ETHYLPIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN-2-YL}METHYL)-6-(2-FLUORINE-4-HYDROXYBENZYL)-4,7-DIOXO-2-(PROP-2-EN-1-YL)HEXAHYDRO-2H-PYRAZINO[2,1-C][1,2,4]TRIAZINE-1(6H)-CARBOXAMIDE | 2016 |
|
RU2723551C2 |
| CRYSTALLINE FGFR4 INHIBITOR AND ITS APPLICATION | 2016 |
|
RU2763328C2 |
